Pharma Stocks

Aurobindo Pharma subsidiary Eugia Steriles faces five US FDA observations

Drug maker Aurobindo Pharma Ltd on Friday (June 19) said the United States Food and Drug Administration (US FDA) has…

Read More »

UCB Stock – Weekly review and pharma peer comparison

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 15:43 CET. Details in the…

Read More »

How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the…

Read More »

LongBio Pharma (Suzhou) (SEHK:1779) Stock Looks Rich With A 65.1x P B Multiple

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.…

Read More »

Why Healthcare Value Stocks Are Back on The Radar?

Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos,…

Read More »

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price…

Read More »

CSPC PHARMA (01093.HK) SYH9056 Tablet Marketing Authorization Application Accepted by NMPA AASTOCKS Financial News

You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…

Read More »

[Click e-Stock] “Pharos iBio Initiates Full-Fledged Technology Transfer Talks with Global Big Pharma”

View original image On June 17, the independent research institute ValueFinder analyzed that Pharos iBio requires a revaluation of its…

Read More »

How New Atumelnant and PALSONIFY Data At Crinetics Pharmaceuticals (CRNX) Has Changed Its Investment Story

In mid-June 2026, Crinetics Pharmaceuticals reported new clinical data at ENDO 2026 showing that oral atumelnant improved key biomarkers in…

Read More »

Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?

In early June 2026, Inceptive Nucleics announced a collaboration with Alnylam Pharmaceuticals worth up to US$2.00 billion, including US$30 million in upfront…

Read More »